Several times recently, President Trump endorsed terminally ill patients’ “right to try” drugs not approved by the FDA: “Patients with terminal conditions, terminal illness, should have access to experimental treatment immediately that could potentially save their lives,” he said in the State of the Union speech.
The federal government weighed in on Idaho’s attempt to skirt provisions in the Affordable Care Act. On Thursday, the head of the Centers for Medicare and Medicaid Services sent a letter to state leaders warning them they were on thin ice with the proposed policies.
Over twenty states filed a lawsuit last week targeted squarely at the heart of Obamacare. The battle is being led by the Attorney General of Texas, Ken Paxton. He argues that because Congress—in the tax reform bill passed into law late last year—effectively ended Obamacare’s requirement that people buy health insurance, the rest of the law cannot stand.
Much of the progress in medicine since I was a medical student has involved expensive, high-tech diagnostic tests and therapies — a trend that has accelerated recently and worries health economists and politicians alike because it boosts healthcare costs.
Suppose you needed to have a CT scan for a sudden, severe headache and partial loss of vision and your doctor asked a nutritionist to read it, rather than a radiologist. Would you trust the diagnosis? Evaluation by a different — and what most would consider a lesser — standard is essentially how a significant amount of research funding is approved by one component of the National Institutes of Health.
The Working Group on Health Care Policy devises public policies that enable more Americans to get better value for their health care dollar and foster appropriate innovations that will extend and improve life.